These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Prospective comparison of (68)Ga-DOTATATE and (18)F-FDOPA PET/CT in patients with various pheochromocytomas and paragangliomas with emphasis on sporadic cases. Archier A; Varoquaux A; Garrigue P; Montava M; Guerin C; Gabriel S; Beschmout E; Morange I; Fakhry N; Castinetti F; Sebag F; Barlier A; Loundou A; Guillet B; Pacak K; Taïeb D Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1248-57. PubMed ID: 26637204 [TBL] [Abstract][Full Text] [Related]
4. (68)Ga-DOTATATE and (18)F-FDG PET/CT in Paraganglioma and Pheochromocytoma: utility, patterns and heterogeneity. Chang CA; Pattison DA; Tothill RW; Kong G; Akhurst TJ; Hicks RJ; Hofman MS Cancer Imaging; 2016 Aug; 16(1):22. PubMed ID: 27535829 [TBL] [Abstract][Full Text] [Related]
5. The Impact of 68Ga-DOTATATE PET/CT Imaging on Management of Patients with Neuroendocrine Tumors: Experience from a National Referral Center in the United Kingdom. Skoura E; Michopoulou S; Mohmaduvesh M; Panagiotidis E; Al Harbi M; Toumpanakis C; Almukhailed O; Kayani I; Syed R; Navalkissoor S; Ell PJ; Caplin ME; Bomanji J J Nucl Med; 2016 Jan; 57(1):34-40. PubMed ID: 26471695 [TBL] [Abstract][Full Text] [Related]
6. PET/CT comparing (68)Ga-DOTATATE and other radiopharmaceuticals and in comparison with CT/MRI for the localization of sporadic metastatic pheochromocytoma and paraganglioma. Janssen I; Chen CC; Millo CM; Ling A; Taieb D; Lin FI; Adams KT; Wolf KI; Herscovitch P; Fojo AT; Buchmann I; Kebebew E; Pacak K Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1784-91. PubMed ID: 26996779 [TBL] [Abstract][Full Text] [Related]
8. The utility of Jaiswal SK; Sarathi V; Malhotra G; Hira P; Shah R; Patil VA; Dalvi A; Prakash G; Lila AR; Shah NS; Bandgar T J Pediatr Endocrinol Metab; 2021 Jan; 34(1):109-119. PubMed ID: 33180042 [TBL] [Abstract][Full Text] [Related]
9. Gallium-68 Dotatate PET/CT is superior to other imaging modalities in the detection of medullary carcinoma of the thyroid in the presence of high serum calcitonin. Tran K; Khan S; Taghizadehasl M; Palazzo F; Frilling A; Todd JF; Al-Nahhas A Hell J Nucl Med; 2015; 18(1):19-24. PubMed ID: 25679074 [TBL] [Abstract][Full Text] [Related]
10. Clinical impact of Tuncel M; Kılıçkap S; Süslü N Ann Nucl Med; 2020 Sep; 34(9):663-674. PubMed ID: 32602032 [TBL] [Abstract][Full Text] [Related]
11. 68Ga-DOTATATE PET/CT in the Localization of Head and Neck Paragangliomas Compared with Other Functional Imaging Modalities and CT/MRI. Janssen I; Chen CC; Taieb D; Patronas NJ; Millo CM; Adams KT; Nambuba J; Herscovitch P; Sadowski SM; Fojo AT; Buchmann I; Kebebew E; Pacak K J Nucl Med; 2016 Feb; 57(2):186-91. PubMed ID: 26564322 [TBL] [Abstract][Full Text] [Related]
12. MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with Sampathirao N; Basu S J Nucl Med Technol; 2017 Mar; 45(1):34-41. PubMed ID: 28154019 [TBL] [Abstract][Full Text] [Related]
13. The diagnostic role of 68Ga-DOTATATE PET/CT in the detection of neuroendocrine tumours. Łapińska G; Bryszewska M; Fijołek-Warszewska A; Kozłowicz-Gudzińska I; Ochman P; Sackiewicz-Słaby A Nucl Med Rev Cent East Eur; 2011; 14(1):16-20. PubMed ID: 21751167 [TBL] [Abstract][Full Text] [Related]
14. Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors. Deppen SA; Liu E; Blume JD; Clanton J; Shi C; Jones-Jackson LB; Lakhani V; Baum RP; Berlin J; Smith GT; Graham M; Sandler MP; Delbeke D; Walker RC J Nucl Med; 2016 May; 57(5):708-14. PubMed ID: 26769865 [TBL] [Abstract][Full Text] [Related]
15. Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors. Panagiotidis E; Alshammari A; Michopoulou S; Skoura E; Naik K; Maragkoudakis E; Mohmaduvesh M; Al-Harbi M; Belda M; Caplin ME; Toumpanakis C; Bomanji J J Nucl Med; 2017 Jan; 58(1):91-96. PubMed ID: 27516446 [TBL] [Abstract][Full Text] [Related]
16. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics. Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215 [TBL] [Abstract][Full Text] [Related]
17. Prevalence of hitherto unknown brain meningioma detected on Parghane RV; Talole S; Basu S World J Nucl Med; 2019; 18(2):160-170. PubMed ID: 31040748 [TBL] [Abstract][Full Text] [Related]